Samuel Kintz Sells 12,500 Shares of Enliven Therapeutics (NASDAQ:ELVN) Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) CEO Samuel Kintz sold 12,500 shares of the business’s stock in a transaction that occurred on Monday, November 17th. The stock was sold at an average price of $21.82, for a total transaction of $272,750.00. Following the completion of the sale, the chief executive officer owned 890,392 shares in the company, valued at $19,428,353.44. The trade was a 1.38% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Samuel Kintz also recently made the following trade(s):

• On Friday, October 17th, Samuel Kintz sold 12,500 shares of Enliven Therapeutics stock. The shares were sold at an average price of $21.33, for a total transaction of $266,625.00.
• On Friday, September 26th, Samuel Kintz sold 3,700 shares of Enliven Therapeutics stock. The stock was sold at an average price of $20.06, for a total transaction of $74,222.00.
• On Tuesday, September 23rd, Samuel Kintz sold 2,800 shares of Enliven Therapeutics stock. The shares were sold at an average price of $20.03, for a total value of $56,084.00.
• On Friday, September 19th, Samuel Kintz sold 1,000 shares of Enliven Therapeutics stock. The shares were sold at an average price of $20.25, for a total value of $20,250.00.
• On Wednesday, September 17th, Samuel Kintz sold 5,000 shares of Enliven Therapeutics stock. The stock was sold at an average price of $19.09, for a total value of $95,450.00.

Enliven Therapeutics Trading Down 2.2%

Shares of Enliven Therapeutics stock traded down $0.49 on Wednesday, reaching $22.10. 440,423 shares of the company were exchanged, compared to its average volume of 422,253. Enliven Therapeutics, Inc. has a fifty-two week low of $13.30 and a fifty-two week high of $26.48. The firm has a market capitalization of $1.31 billion, a price-to-earnings ratio of -12.01 and a beta of 0.80. The stock has a fifty day moving average price of $20.32 and a 200-day moving average price of $20.11.

Enliven Therapeutics (NASDAQ:ELVN) last released its quarterly earnings results on Wednesday, November 12th. The company reported ($0.32) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.11. On average, equities analysts anticipate that Enliven Therapeutics, Inc. will post -1.95 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Enliven Therapeutics

A number of institutional investors have recently modified their holdings of ELVN. Vestal Point Capital LP grew its holdings in shares of Enliven Therapeutics by 364.0% during the 3rd quarter. Vestal Point Capital LP now owns 1,160,000 shares of the company’s stock valued at $23,745,000 after acquiring an additional 910,000 shares in the last quarter. Polar Capital Holdings Plc boosted its position in Enliven Therapeutics by 1.5% during the third quarter. Polar Capital Holdings Plc now owns 3,095,007 shares of the company’s stock valued at $63,355,000 after purchasing an additional 44,713 shares during the last quarter. Millennium Management LLC boosted its position in Enliven Therapeutics by 19.8% during the third quarter. Millennium Management LLC now owns 381,405 shares of the company’s stock valued at $7,807,000 after purchasing an additional 62,956 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in Enliven Therapeutics by 10.6% in the third quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 19,529 shares of the company’s stock valued at $400,000 after purchasing an additional 1,873 shares in the last quarter. Finally, HighVista Strategies LLC increased its position in Enliven Therapeutics by 83.1% in the 3rd quarter. HighVista Strategies LLC now owns 259,135 shares of the company’s stock worth $5,304,000 after purchasing an additional 117,619 shares during the last quarter. Institutional investors and hedge funds own 95.08% of the company’s stock.

Analyst Ratings Changes

ELVN has been the topic of several analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Enliven Therapeutics in a research report on Wednesday, October 8th. Wall Street Zen upgraded Enliven Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday. Five analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, Enliven Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $41.20.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.